Literature DB >> 15774491

Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression.

Silvia I Vanzulli1, Rocío Soldati, Roberto Meiss, Lucas Colombo, Alfredo A Molinolo, Claudia Lanari.   

Abstract

In this paper we demonstrate, using the C7-2-HI metastatic transplantable ductal mammary tumor, that endocrine therapy can induce complete regression of spontaneous lymph node and lung metastases in a mouse model of breast cancer progression. This tumor expresses high levels of estrogen and progesterone receptors and shows a high incidence of early axillary lymph nodes and lung metastases; using this model we had previously shown complete tumor regression of subcutaneous implants. Interestingly, although the metastases showed a more differentiated histology as compared with the primary growth, they underwent complete regression when treated with estrogens or antiprogestins. This phenomenon was associated with sustained cytostasis and apoptosis accompanied by increases in p21 and p27 expression and early tissue remodeling. These results highlight the essential role of PR in regulating cell proliferation in this model as well as its possible use as therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15774491     DOI: 10.1093/carcin/bgi060

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  11 in total

1.  [Breast cancer metastases in the head and neck region].

Authors:  P J Schuler; S Heikaus; U Friebe-Hoffmann; T K Hoffmann; J Greve; T Klenzner; J Schipper; K Scheckenbach
Journal:  HNO       Date:  2010-08       Impact factor: 1.284

2.  Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer.

Authors:  Juan P Cerliani; Silvia I Vanzulli; Cecilia Pérez Piñero; María C Bottino; Ana Sahores; Myriam Nuñez; Romina Varchetta; Rubén Martins; Eduardo Zeitlin; Stephen M Hewitt; Alfredo A Molinolo; Claudia Lanari; Caroline A Lamb
Journal:  Breast Cancer Res Treat       Date:  2011-11-29       Impact factor: 4.872

3.  Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.

Authors:  Maria Laura Polo; Maria Victoria Arnoni; Marina Riggio; Victoria Wargon; Claudia Lanari; Virginia Novaro
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

4.  A new strategy for selective targeting of progesterone receptor with passive antagonists.

Authors:  Junaid A Khan; Abdellatif Tikad; Michel Fay; Abdallah Hamze; Jérôme Fagart; Nathalie Chabbert-Buffet; Geri Meduri; Larbi Amazit; Jean-Daniel Brion; Mouad Alami; Marc Lombès; Hugues Loosfelt; Marie-Edith Rafestin-Oblin
Journal:  Mol Endocrinol       Date:  2013-04-11

Review 5.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

6.  Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort.

Authors:  Jacques Bonneterre; Jacques Bosq; Philippe Jamme; Alexander Valent; Erard M Gilles; Alexander A Zukiwski; Suzanne A W Fuqua; Carol A Lange; Joyce O'Shaughnessy
Journal:  ESMO Open       Date:  2016-08-22

7.  Novel, low cost, highly effective, handmade steroid pellets for experimental studies.

Authors:  Ana Sahores; Guillermina M Luque; Victoria Wargon; María May; Alfredo Molinolo; Damasia Becu-Villalobos; Claudia Lanari; Caroline A Lamb
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

8.  BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer.

Authors:  Jiahua Jiang; Anita Thyagarajan-Sahu; Jagadish Loganathan; Isaac Eliaz; Colin Terry; George E Sandusky; Daniel Sliva
Journal:  Oncol Rep       Date:  2012-07-26       Impact factor: 3.906

9.  Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton.

Authors:  Xiao-Dong Fu; Maria S Giretti; Chiara Baldacci; Silvia Garibaldi; Marina Flamini; Angel Matias Sanchez; Angiolo Gadducci; Andrea R Genazzani; Tommaso Simoncini
Journal:  PLoS One       Date:  2008-07-30       Impact factor: 3.240

10.  The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.

Authors:  Gonzalo Sequeira; Silvia I Vanzulli; Paola Rojas; Caroline Lamb; Lucas Colombo; Maria May; Alfredo Molinolo; Claudia Lanari
Journal:  Oncotarget       Date:  2014-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.